Wednesday, 18 June 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 18 June 2025
News

New warning hits blockbuster drugs

Posted 6 June 2025 PM

The TGA has added a class-wide warning for GLP-1 and dual GIP/GLP-1 receptor agonists about the risk of aspiration during general anaesthesia and deep sedation after conducting an independent assessment.

GLP-1 medicines currently marketed in Australia include three diabetes treatments – Novo Nordisk’s Ozempic and Victoza, plus Eli Lilly’s Trulicity – along with Novo Nordisk’s Saxenda and Wegovy, which are approved for chronic weight management in patients who are obese or overweight.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (12)

Clinical & Medical, R&D (13)

Regulatory, Pharmacovigilance & QA (3)

Other (16)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.